151 related articles for article (PubMed ID: 36394890)
21. Adalimumab treatment for chronic recurrent Vogt-Koyanagi-Harada disease with sunset glow fundus: A multicenter study.
Takeuchi M; Nakai S; Usui Y; Namba K; Suzuki K; Harada Y; Kusuhara S; Kaburaki T; Tanaka R; Takeuchi M; Mizuki N; Nakai K; Goto H; Herbort CP
Saudi J Ophthalmol; 2022; 36(4):380-386. PubMed ID: 36618573
[TBL] [Abstract][Full Text] [Related]
22. Long-term changes of choroidal blood flow velocity in Vogt-Koyanagi-Harada disease.
Abe S; Nakamura T; Okumura E; Oiwake T; Okada AA; Hayashi A
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1933-1939. PubMed ID: 34982220
[TBL] [Abstract][Full Text] [Related]
23. Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome.
Rubsamen PE; Gass JD
Arch Ophthalmol; 1991 May; 109(5):682-7. PubMed ID: 2025171
[TBL] [Abstract][Full Text] [Related]
24. Influence of early cerebrospinal fluid-guided diagnosis and early high-dose corticosteroid therapy on ocular outcomes of Vogt-Koyanagi-Harada disease.
Miyanaga M; Kawaguchi T; Shimizu K; Miyata K; Mochizuki M
Int Ophthalmol; 2007; 27(2-3):183-8. PubMed ID: 17476572
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of patients with acute Vogt-Koyanagi-Harada disease treated with intravenous corticosteroid pulse followed by the slow tapering of oral corticosteroid therapy.
Fushitsu R; Ishibazawa A; Murono M; Kinouchi R
Int Ophthalmol; 2023 Feb; 43(2):431-440. PubMed ID: 35869402
[TBL] [Abstract][Full Text] [Related]
26. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.
Nakayama M; Keino H; Watanabe T; Okada AA
Br J Ophthalmol; 2019 Feb; 103(2):274-278. PubMed ID: 29666121
[TBL] [Abstract][Full Text] [Related]
27. A Novel Risk Stratification-Based Immunomodulatory Treatment Strategy for Vogt-Koyanagi-Harada Disease.
Jin K; Liang A; Song H; Xiao F; Gao F; Han X; Zhang M; Zhao C
Am J Ophthalmol; 2024 Jun; 262():25-33. PubMed ID: 38369223
[TBL] [Abstract][Full Text] [Related]
28. Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature.
Rahman N; Artiaga JCM; Bouras K; Luis J; Rees A; Westcott M
J Ophthalmic Inflamm Infect; 2023 May; 13(1):27. PubMed ID: 37204477
[TBL] [Abstract][Full Text] [Related]
29. Vogt-Koyanagi-Harada disease: recurrence rates after initial-onset disease differ according to treatment modality and geographic area.
Herbort CP; Tugal-Tutkun I; Khairallah M; Abu El Asrar AM; Pavésio CE; Soheilian M
Int Ophthalmol; 2020 Sep; 40(9):2423-2433. PubMed ID: 32418076
[TBL] [Abstract][Full Text] [Related]
30. Chronic Recurrent Vogt-Koyanagi-Harada Disease and Development of 'Sunset Glow Fundus' Predict Worse Retinal Sensitivity.
Abu El-Asrar AM; Al Mudhaiyan T; Al Najashi AA; Hemachandran S; Hariz R; Mousa A; Al-Muammar A
Ocul Immunol Inflamm; 2017 Aug; 25(4):475-485. PubMed ID: 27003480
[TBL] [Abstract][Full Text] [Related]
31. Reactivation of previously controlled Vogt-Koyanagi-Harada disease more than 46 years following COVID-19 vaccination: a case study.
Muto T; Sakamoto M; Imaizumi S; Kamoi K
J Int Med Res; 2024 Jan; 52(1):3000605231221081. PubMed ID: 38170955
[TBL] [Abstract][Full Text] [Related]
32. Depigmented atrophic lesions in sunset glow fundi of Vogt-Koyanagi-Harada disease.
Inomata H; Rao NA
Am J Ophthalmol; 2001 May; 131(5):607-14. PubMed ID: 11336935
[TBL] [Abstract][Full Text] [Related]
33. Predictive Biomarker for Progression Into the Sunset Glow Fundus of Vogt-Koyanagi-Harada Disease, Using Adaptive Binarization of Fundus Photographs.
Komuku Y; Ishikawa H; Ide A; Matsuoka T; Fukuyama H; Okadome T; Gomi F
Transl Vis Sci Technol; 2020 Oct; 9(11):10. PubMed ID: 33133773
[TBL] [Abstract][Full Text] [Related]
34. Incidence, Risk Factors and Surgical Outcomes of Cataract among Patients with Vogt-Koyanagi-Harada Disease.
AlBloushi AF; Alfawaz AM; AlZaid A; Alsalamah AK; Gikandi PW; Abu El-Asrar AM
Ocul Immunol Inflamm; 2021 Jan; 29(1):128-136. PubMed ID: 31638886
[No Abstract] [Full Text] [Related]
35. [Vogt-Koyanagi-Harada syndrome in children].
Laghmari M; Karim A; Ibrahimy W; Essakalli NH; Mohcine Z
J Fr Ophtalmol; 2002 Jun; 25(6):636-40. PubMed ID: 12223954
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic window of opportunity in the acute uveitic phase of Vogt-Koyanagi-Harada disease: Prevention of late autoimmune complications by early intervention.
Abu El-Asrar AM; Al Rashed FA; AlBloushi AF; Tobaigy MF; Gikandi PW; Herbort CP; Opdenakker G
Acta Ophthalmol; 2023 Mar; 101(2):e236-e245. PubMed ID: 36128841
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of B Cell Depletion Therapy with Rituximab in Refractory Chronic Recurrent Uveitis Associated with Vogt-Koyanagi-Harada Disease.
Abu El-Asrar AM; Dheyab A; Khatib D; Struyf S; Van Damme J; Opdenakker G
Ocul Immunol Inflamm; 2022 Apr; 30(3):750-757. PubMed ID: 32990482
[TBL] [Abstract][Full Text] [Related]
38. Presumed Vogt-Koyanagi-Harada disease with unilateral ocular involvement: report of three cases.
Usui Y; Goto H; Sakai J; Takeuchi M; Usui M; Rao NA
Graefes Arch Clin Exp Ophthalmol; 2009 Aug; 247(8):1127-32. PubMed ID: 19308440
[TBL] [Abstract][Full Text] [Related]
39. Quantitative evaluation of "sunset glow" fundus in Vogt-Koyanagi-Harada disease.
Suzuki S
Jpn J Ophthalmol; 1999; 43(4):327-33. PubMed ID: 10482481
[TBL] [Abstract][Full Text] [Related]
40. Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination.
Accorinti M; Saturno MC; Manni P
Ocul Immunol Inflamm; 2022 Jul; 30(5):1228-1233. PubMed ID: 35201950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
